Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, continues to progress its RNA-based therapeutic pipeline with multiple programs in obesity, genetic liver and lung diseases, neuromuscular disorders, and neurodegeneration. With a proprietary platform focused on RNA editing and interference, the company has outlined a series of upcoming clinical milestones that could shape its trajectory over the next 12-18 months.
Obesity Program: WVE-007 Shows Durable Target Engagement
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.